Eam Investors, LLC Akebia Therapeutics, Inc. Transaction History

Eam Investors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$1.27 - $2.24 $544,257 - $959,949	428,549 New	428,549 $784,000
Q3 2020 Nov 13, 2020	SELL	$2.39 - $13.08 $481,635 - $2.64 Million	-201,521 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$6.67 - $13.58 $1.34 Million - $2.74 Million	201,521 New	201,521 $2.74 Million
Q1 2018 May 14, 2018	SELL	$9.53 - $15.68 $1.72 Million - $2.83 Million	-180,503 Closed	0 $0
Q4 2017 May 21, 2018	SELL	$14.24 - $19.59 $758,052 - $1.04 Million	-53,234 Reduced 22.78%	180,503 $2.68 Million
Q4 2017 Feb 12, 2018	SELL	$14.24 - $19.59 $24,677 - $33,949	-1,733 Reduced 0.74%	233,737 $3.48 Million
Q3 2017 Nov 08, 2017	BUY	$13.06 - $19.67 $3.08 Million - $4.63 Million	235,470	235,470 $4.63 Million

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $417M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.